AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20350945
Drug: MGAWN1 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGAWN1 (30 mg/kg)
Trial: 18034842
Drug: Vildagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (100 mg daily, given as equally divided doses)
Trial: 18034842
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg daily, given as a single q.d. dose)
Trial: 11440493
Drug: Dipyridamole alone
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole alone at a dose of 75 mg t.i.d. orally for 8 weeks
Trial: 7761963
Drug: Taleum (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taleum (sodium cromoglycate) inhalation aerosol
Trial: 7761963
Drug: Intal powder
RxNorm normalized name: cromolyn sodium Inhalation Solution [Intal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intal powder inhaled with the aid of a spinhaler
Trial: 29371479
Drug: Daratumumab in
RxNorm normalized name: daratumumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab in combination with lenalidomide and dexamethasone
Trial: 29371479
Drug: Daratumumab in
RxNorm normalized name: daratumumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab in combination with bortezomib and dexamethasone
Trial: 24243397
Drug: Multicomponent exercise
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent exercise program (4 weeks of walking, balance and cognitive exercises, followed by 4 weeks of resistance exercise performed twice weekly at 20-50% of 1RM)
Trial: 20027105
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg rolofylline administered by intravenous infusion over 2 hours
Trial: 15964408
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil 3 g daily (n = 22)
Trial: 15964408
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil 2 g daily (n = 94)
Trial: 15964408
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil 3 g daily (n = 21)
Trial: 15964408
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil 2 g daily (n = 29)
Trial: 11728846
Drug: Maintenance medication
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance medication
Trial: 29589086
Drug: Subchondral bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subchondral bone marrow concentrate injection (average of 6500 MSCs/mL)
Trial: 24630419
Drug: Alvimopan 12
RxNorm normalized name: alvimopan 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvimopan 12 mg (maximum: 15 inpatient doses)
Trial: 22906179
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care intervention with low-intensity psychological treatments delivered by IAPT services.
Trial: 19889809
Drug: High (n-3)LCPUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High (n-3)LCPUFA beverage (1 g fat/kg body weight)
Trial: 19889809
Drug: Low (n-3)LCPUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low (n-3)LCPUFA beverage (1 g fat/kg body weight)
Trial: 16940036
Drug: Mono-protease inhibitor
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mono-protease inhibitor use
Trial: 16940036
Drug: Dual-protease inhibitor
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-protease inhibitor use
Trial: 16319804
Drug: Maximum dose
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum dose glibenclamide (control)
Trial: 3813951
Drug: Aminocaproic acid
RxNorm normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminocaproic acid (Amicar), 100 mg/kg every four hours, up to a maximum of 30 g/d for five days
Trial: 2665584
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) 1,500 micrograms/day
Trial: 17046384
Drug: Tanaproget 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanaproget 0.1 mg
Trial: 17046384
Drug: Tanaproget 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanaproget 0.3 mg
Trial: 17046384
Drug: Tanaproget 1
RxNorm normalized name: Tanaproget
DrugBank: Tanaproget (DB04787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanaproget 1 mg
Trial: 17046384
Drug: Tanaproget 3
RxNorm normalized name: Tanaproget
DrugBank: Tanaproget (DB04787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanaproget 3 mg
Trial: 17046384
Drug: Tanaproget 7
RxNorm normalized name: Tanaproget
DrugBank: Tanaproget (DB04787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanaproget 7 mg
Trial: 17046384
Drug: Tanaproget 15
RxNorm normalized name: Tanaproget
DrugBank: Tanaproget (DB04787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanaproget 15 mg
Trial: 14685868
Drug: Painful contractions
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Painful contractions with 6% hypertonic saline injection
Trial: 8487073
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus CCNU (100 mg/sq m every 6 weeks)
Trial: 2963742
Drug: alpha-human atrial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-human atrial natriuretic polypeptide (alpha-hANP) infusion
Trial: 23730858
Drug: Foot reflexology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot reflexology treatment for 1 week in three sessions following haemodialysis, each session lasting approximately 30 minutes
Trial: 21262048
Drug: 8 weekly
RxNorm normalized name: Weekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 weekly home visits focused on improving caregiver sensitivity
Trial: 19793860
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid (IFA; 60 mg ferrous fumarate and 400 microg folic acid)
Trial: 16409326
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: immersion in 4% hydrofluoric acid gel for 60 s and silanization for 60 s
Trial: 16409326
Drug: Group 4:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 4: silanization of the post surface for 60 s and application of the bonding agent G-Bond
Trial: 15243010
Drug: Controlled-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release methylphenidate (MPH), 1.0 mg/kg, once daily
Trial: 11804430
Drug: ketoconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoconazole (400 mg daily) followed by clomiphene (100 mg/day)
Trial: 28437262
Drug: Lumbar Epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar Epidural Injection Trainer (Erler‐Zimmer, Lauf, Germany)
Trial: 26077237
Drug: Bevacizumab monotherapy
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab monotherapy 10 mg/kg IV every 2 weeks
Trial: 26077237
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg IV every 2 weeks and temsirolimus 25 mg IV every week
Trial: 26077237
Drug: Bevacizumab 5
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 5 mg/kg IV every 2 weeks and sorafenib 200 mg orally twice daily
Trial: 26077237
Drug: Sorafenib 200
RxNorm normalized name: sorafenib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 200 mg twice daily and temsirolimus 25 mg IV weekly
Trial: 23599320
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL of autologous whole blood injected
Trial: 16518424
Drug: Topical histamine
RxNorm normalized name: histamine Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical histamine dihydrochloride (HDC) gel
Trial: 10755495
Drug: Metformin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2.5 g/d) + Rosiglitazone (4 mg/d)
Trial: 10755495
Drug: Metformin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2.5 g/d) + Rosiglitazone (8 mg/d)
Trial: 10755495
Drug: Metformin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2.5 g/d) + Placebo
Trial: 8969976
Drug: Tacrine (Cognex)
RxNorm normalized name: tacrine Oral Capsule [Cognex]
DrugBank: Tacrine (DB00382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrine (Cognex) treatment
Trial: 17969466
Drug: Sleep restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep restriction combined with 0.035 g/dL low-dose alcohol
Trial: 17969466
Drug: Sleep restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep restriction combined with 0.025 g/dL low-dose alcohol
Trial: 13680286
Drug: Immunochemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunochemotherapy with oral PSK (3 g per day) followed by oral 5‐FU (200 mg/body per day)
Trial: 13680286
Drug: Intermittent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent chemotherapy with oral 5‐FU (200 mg per day) followed by 4‐week rest
Trial: 9346380
Drug: Exercise renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise renal rehabilitation program (ERRP) consisting of 3 weekly sessions for 6 months
Trial: 1783082
Drug: Diamorphine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine 2.5 mg
Trial: 1783082
Drug: Diamorphine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine 5 mg
Trial: 1783082
Drug: Diamorphine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine 7.5 mg
Trial: 30925876
Drug: CBG-CS-2 (1.68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBG-CS-2 (1.68 g/day for 8 weeks)
Trial: 26771888
Drug: Carrying at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrying at least one minor allele of rs2069762 (G) in IL2
Trial: 25114296
Drug: IDegLira +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDegLira + metformin
Trial: 25114296
Drug: IDeg +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDeg + metformin
Trial: 22934754
Drug: Topical rapamycin
RxNorm normalized name: natamycin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical rapamycin (0.003% and 0.015%)
Trial: 12153372
Drug: Current high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current high daily stress, perceived negative impact of military life on physical or mental health, and physician-diagnosed chronic illnesses
Trial: 7948057
Drug: Experimental day-treatment
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental day-treatment group
Trial: 29433562
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump therapy for 2 weeks
Trial: 27455955
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg twice weekly for 12 weeks followed by etanercept 25 mg twice weekly for 12 weeks (ETN-ETN)
Trial: 27455955
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg twice weekly plus acitretin 10 mg twice daily for 24 weeks (ETN-ACT)
Trial: 27455955
Drug: Acitretin 10
RxNorm normalized name: acitretin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin 10 mg twice daily for 24 weeks (ACT)
Trial: 22633033
Drug: Specialised care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialised care of cognitive behaviour therapy with sound-focused tinnitus retraining therapy
Trial: 21098771
Drug: Combination training
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination training (aerobic and resistance training)
Trial: 15966464
Drug: SPP301 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPP301 20 mg
Trial: 15966464
Drug: SPP301 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPP301 40 mg
Trial: 15966464
Drug: SPP301 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPP301 60 mg
Trial: 8929751
Drug: Drug use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug use in case of illness during pregnancy before admission to hospital for delivery
Trial: 8929751
Drug: Drug administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug administration under delivery
Trial: 8929751
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy of chronic diseases in pregnancy
Trial: 8929751
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of nursing women
Trial: 6538742
Drug: Meat (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meat (75 g)
Trial: 6538742
Drug: Cauliflower (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cauliflower (65 mg ascorbic acid)
Trial: 6538742
Drug: Pure ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pure ascorbic acid (50 mg)
Trial: 6538742
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate (6 mg)
Trial: 6538742
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid (1 g)
Trial: 30059778
Drug: Epidural Steroids
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural Steroids (ES)
Trial: 16956917
Drug: 16-week treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16-week treatment with peginterferon alpha-2a (180 mug/week) and weight-based ribavirin (1000-1200 mg/day)
Trial: 16956917
Drug: 24-week treatment
RxNorm normalized name: Weeks and Leo Complete Lice Treatment KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-week treatment with peginterferon alpha-2a (180 mug/week) and weight-based ribavirin (1000-1200 mg/day)
Trial: 16956917
Drug: 16-week treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16-week treatment with RVR
Trial: 16956917
Drug: 24-week treatment
RxNorm normalized name: Weeks and Leo Complete Lice Treatment KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-week treatment with RVR
Trial: 15542934
Drug: E3/pravastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E3/pravastatin (2 mg E3 and 10 mg pravastatin)
Trial: 15542934
Drug: E3 (2
RxNorm normalized name: Estradiol 3-benzoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E3 (2 mg)
Trial: 9856958
Drug: Quinapril (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (40 mg BID)
Trial: 2194052
Drug: 10% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% lidocaine aqueous gel with 3% glycyrrhetinic acid 3‐0 hemiphthalate disodium (GAHPh)
Trial: 2194052
Drug: Plain 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain 10% lidocaine aqueous gel without GAHPh
Trial: 27397584
Drug: F‐SET (False
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F‐SET (False Safety Behavior Elimination Therapy)
Trial: 26201190
Drug: SIT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIT group (n = 34) received medication and 3 years of standardized allergen vaccine therapy
Trial: 26201190
Drug: ST group
RxNorm normalized name: ST-36
DrugBank: ST-36 (DB17275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST group (n = 34) received symptomatic therapy
Trial: 23352749
Drug: 640 U
RxNorm normalized name: metaxalone 640 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 640 U alum‐adjuvant EV71 vaccine
Trial: 23352749
Drug: 320 U
RxNorm normalized name: beta carotene 14320 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 U alum‐adjuvant EV71 vaccine
Trial: 15623060
Drug: Biolok implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biolok implants
Trial: 9296421
Drug: Diltiazem (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (30 mg, per os)
Trial: 9296421
Drug: Nimodipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (60 mg, per os)
Trial: 9296421
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg, per os)
Trial: 9296421
Drug: Morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10 mg/70 kg, intravenously)
Trial: 3755412
Drug: Molsidomine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (4 mg, 2 tablets)
Trial: 20227891
Drug: Intraoperative fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative fentanyl administration
Trial: 17214049
Drug: Ginger (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (3 capsules of 0.5 g ginger powder each)
Trial: 17214049
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 capsules)
Trial: 8853725
Drug: Zidovudine and
RxNorm normalized name: zidovudine and lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine and aciclovir therapy
Trial: 8853725
Drug: Oral sexual
RxNorm normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sexual practices
Trial: 1537726
Drug: Acetazolamide (ACZ)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (ACZ) 1,000 mg intravenous injection
Trial: 6594722
Drug: Endocervical PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Endocervical PGE2 gel (400 micrograms)
Trial: 6594722
Drug: Extra-amniotic PGE2
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-amniotic PGE2 gel (400 or 800 micrograms)
Trial: 6594722
Drug: Control (inactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (inactive gel)
Trial: 24102103
Drug: Humor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humor therapy program with professional performers (ElderClowns) and trained facility staff (LaughterBosses) for a minimum of nine 2-hour sessions over 12 weeks.
Trial: 19260050
Drug: IGIV‐C (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV‐C (10% caprylate/chromatography purified); administered every 3 weeks for up to 24 weeks
Trial: 19260050
Drug: Placebo; administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; administered every 3 weeks for up to 24 weeks
Trial: 15516697
Drug: Trandolapril plus
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trandolapril plus verapamil (2 mg per day + 180 mg per day)
Trial: 15516697
Drug: Trandolapril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (2 mg per day)
Trial: 15516697
Drug: Verapamil (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (240 mg per day)
Trial: 9771862
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (260 nmol, approximately 4000 IU) daily for 14 days
Trial: 9771862
Drug: Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin D2 (260 nmol, approximately 4000 IU) daily for 14 days
Trial: 7921339
Drug: Cinnarizine 25
RxNorm normalized name: cinnarizine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine 25 mg
Trial: 7921339
Drug: Cinnarizine 25
RxNorm normalized name: cinnarizine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine 25 mg + 10 mg domperidone
Trial: 7921339
Drug: Cinnarizine 25
RxNorm normalized name: cinnarizine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine 25 mg + 1 transdermal scopolamine patch
Trial: 3378855
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg/die/os
Trial: 3378855
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg/die/os
Trial: 26276754
Drug: Metformin 1,700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1,700 mg once daily for 28 days
Trial: 19595060
Drug: Anti-Cit‐CII antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Cit‐CII antibody
Trial: 19595060
Drug: Anti-CII antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CII antibody